Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium valproate versus escitalopram for acute major depressive disorder with mixed features
ChiCTR2100048741Phase 4Not yet recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in major depressive disorder (MDD) comparing Escitalopram arm with Sodium valproate arm (2 arms). Primary endpoints: Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 and 12 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
valproic acidescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100048741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048741.